Microcap Ledger

Tickers · $SNES

SenesTech, Inc. $SNES

By Microcap Ledger desk · CIK 0001680378

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Agricultural Chemicals
Headquarters
Phoenix, AZ
Fiscal year end
December 31
Shares outstanding
5,423,542 [10-Q 2026-08-06]
as of 2026-08-04

Sources: [10-K 2026-03-13]

What the company doesAI summary of filing

SenesTech develops and commercializes fertility control products for managing rat and mouse populations. The company's primary revenue-generating product is Evolve, a soft bait containing cottonseed oil that was launched in January 2024 and reduces fertility in both male and female rodents; Evolve Rat is authorized for sale in 48 states and territories, and Evolve Mouse, introduced in May 2024, is authorized in 37 states and territories. The company also markets ContraPest, a liquid bait containing VCD and triptolide that received EPA registration in August 2016 and is registered in all 50 states and major U.S. territories. SenesTech generates revenue through sales of these fertility control products to pest management providers, agricultural operators, industrial facilities, and retail channels, positioning them as alternatives to traditional lethal rodenticides and as tools for integrated pest management programs. [10-K 2026-03-13]

Segments: Evolve Rat, Evolve Mouse, ContraPest, Elevate Bait System

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$1.26M−$3.90M −$3.64M$5.08M[10-Q 2026-08-06]
FY ended Dec 2025$2.22M−$6.38M −$5.75M$7.58M[10-K 2026-03-13]
FY ended Dec 2024$1.86M−$6.18M −$6.03M$1.31M[10-K 2026-03-13]
Quarterly cash burn
−$1.82M
Cash runway Estimate
~8.4 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-081,033,644[10-Q 2024-11-12]
2025-03-111,746,930[10-K 2025-03-13]
2025-05-051,775,930[10-Q 2025-05-08]
2025-08-055,223,015[10-Q 2025-08-08]
2025-11-075,223,015[10-Q 2025-11-10]
2026-03-115,303,426[10-K 2026-03-13]
2026-05-115,303,426[10-Q 2026-05-13]
2026-08-045,423,542[10-Q 2026-08-06]
Shelf registration
S-3 filed 2025-08-15; declared effective 2025-08-22 [S-3 2025-08-15]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-28Edell Michaelbuy2,000$0.64[4 2026-09-29]
2026-09-14Edell Michaelbuy1,000$0.84[4 2026-09-15]
2026-09-09Edell Michaelbuy1,000$0.89[4 2026-09-10]
2026-09-09Edell Michaelbuy1,000$0.85[4 2026-09-10]
2026-08-14Edell Michaelbuy1,000$1.21[4 2026-08-17]
2026-08-07Glenbrook Capital Managementbuy6,490$1.30[4 2026-08-10]
2026-08-06Glenbrook Capital Managementbuy15,000$1.30[4 2026-08-10]
2026-07-20Glenbrook Capital Managementbuy35,000$1.47[4 2026-07-22]
2026-07-07Edell Michaelbuy1,000$1.43[4 2026-07-08]
2026-06-30Glenbrook Capital Managementbuy35,000$1.51[4 2026-07-02]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-08-0610-QQuarterly report
2026-08-058-KResults of operations
2026-08-038-KResults of operations
2026-07-2313DBeneficial ownership report (5%+ holder)
2026-06-108-KShareholder vote results
2026-05-1310-QQuarterly report
2026-05-128-KResults of operations
2026-05-078-KDirector or officer change
2026-04-29DEF 14AProxy statement
2026-03-1813G/ABeneficial ownership report (5%+ holder)
2026-03-1310-KAnnual report
2026-03-128-KResults of operations

Facts as of . Small caps move fast; check the latest filings.